Standardization in Clinical Trials: Optimizing Biospecimen Collection, Preservation, and Export

Biospecimen standardization has emerged as a critical priority in clinical trials, with the implementation of ICH E6(R3) guidelines in 2025 marking a paradigm shift toward enhanced data integrity and quality management. This comprehensive review examines current best practices, regulatory frameworks, and emerging technologies in biospecimen collection, preservation, and international transport. We explore the impact of pre-analytical variables on sample quality, evaluate international standardization initiatives including ISBER Best Practices and NCI Evidence-Based Practices, and analyze the complex regulatory landscape governing biospecimen export. The integration of artificial intelligence and digital biobanking technologies presents unprecedented opportunities for quality control and sample tracking. This review synthesizes evidence-based recommendations for implementing standardized protocols across the biospecimen lifecycle, from collection through analysis, while addressing practical considerations for multi-site clinical trials. By establishing harmonized practices, the clinical research community can enhance data reliability, facilitate global collaboration, and ultimately improve the translation of research findings into clinical practice.

Biospecimen Standardization, Clinical Trials, ICH E6(R3),

1. Campbell LD, Astrin JJ, DeSouza Y, et al. The 2018 revision of the ISBER best practices: Summary of changes and the editorial team's development process. Biopreservation and Biobanking. 2018;16(1):3-6. doi:10.1089/bio.2017.0138 [Google Scholar] [Crossref]

2. Moore HM, Kelly AB, Jewell SD, et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119(2):92-101. doi:10.1002/cncy.20147 [Google Scholar] [Crossref]

3. Sion SI, Nguyen-Phan T, Fortin M, Mes-Masson AM, Zhang K. Transforming biospecimen management: A roadmap for integrated sample traceability in the era of global research. Biopreservation and Biobanking. 2025. doi:10.1177/19475535251366364 [Google Scholar] [Crossref]

4. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R3). ICH; January 2025. https://database.ich.org/sites/default/files/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf [Google Scholar] [Crossref]

5. European Medicines Agency. ICH E6(R3) Good Clinical Practice. Published January 27, 2025. https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline [Google Scholar] [Crossref]

6. Bass BP, Engel KB, Greytak SR, Moore HM. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissues: The experience from the Biospecimen Preanalytical Variables (BPV) program. Arch Pathol Lab Med. 2014;138(11):1520-1530. doi:10.5858/arpa.2013-0691-OA [Google Scholar] [Crossref]

7. Carithers LJ, Agarwal R, Guan P, et al. The Biospecimen Preanalytical Variables Program: A multiassay comparison of effects of delay to fixation and fixation duration on nucleic acid quality. Arch Pathol Lab Med. 2019;143(5):566-576. doi:10.5858/arpa.2018-0125-OA [Google Scholar] [Crossref]

8. Greytak SR, Engel KB, Bass BP, Moore HM. Accuracy of molecular data generated with FFPE biospecimens: Lessons from the literature. Cancer Res. 2015;75(8):1541-1547. doi:10.1158/0008-5472.CAN-14-2378 [Google Scholar] [Crossref]

9. Betsou F, Gunter E, Clements J, et al. Identification of evidence-based biospecimen quality-control tools: A report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. J Mol Diagn. 2013;15(1):3-16. doi:10.1016/j.jmoldx.2012.06.008 [Google Scholar] [Crossref]

10. Vaught J, Kelly A, Hewitt R. A review of international biobanks and networks: Success factors and key benchmarks. Biopreservation and Biobanking. 2009;7(3):143-150. doi:10.1089/bio.2009.0026 [Google Scholar] [Crossref]

11. National Cancer Institute Biorepositories and Biospecimen Research Branch. Biospecimen Pre-analytical Variables Program. https://biospecimens.cancer.gov/programs/bpv/default.asp. Accessed October 2025. [Google Scholar] [Crossref]

12. U.S. Food and Drug Administration, U.S. Customs and Border Protection. Importing Biological Materials into the United States. Updated 2025. https://www.cbp.gov/border-security/protecting-agriculture/importing-biological-materials-united-states [Google Scholar] [Crossref]

13. International Air Transport Association. Dangerous Goods Regulations. 66th Edition. IATA; 2025. [Google Scholar] [Crossref]

14. Office of Inspector General, U.S. Department of Health and Human Services. NIH Recipients Conducting Biospecimen Research: Gaps in Emergency Planning and Reporting. Report OEI-04-23-00280. Published June 2025. [Google Scholar] [Crossref]

15. Li J, Greytak SR, Guan P, et al. Formalin fixation, delay to fixation, and time in fixative adversely impact copy number variation analysis by aCGH. Biopreserv Biobank. 2022;20(5):472-480. doi:10.1089/bio.2021.0158 [Google Scholar] [Crossref]

16. Bagchi A, Madaj Z, Engel KB, et al. Impact of preanalytical factors on the measurement of tumor tissue biomarkers using immunohistochemistry. J Histochem Cytochem. 2021;69(5):297-320. doi:10.1369/0022155421995600 [Google Scholar] [Crossref]

17. Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2011;135(5):537-543. doi:10.5858/2010-0702-RAIR.1 [Google Scholar] [Crossref]

18. Simeon-Dubach D, Watson P. Biobanking 3.0: Evidence based and customer focused biobanking. Clin Biochem. 2014;47(4-5):300-308. doi:10.1016/j.clinbiochem.2013.12.018 [Google Scholar] [Crossref]

19. Janjigian YY, Titmuss E, Loree J, et al. Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring. Am Soc Clin Oncol Educ Book. 2025;45:e481114. doi:10.1200/EDBK-25-481114 [Google Scholar] [Crossref]

20. Precision for Medicine, PathAI. Strategic collaboration to advance AI-powered clinical trial services and biospecimen products. Press release. April 25, 2025. [Google Scholar] [Crossref]

21. CloudLIMS. Integrate AI with biospecimen management systems to transform biobanking. Published July 29, 2025. https://cloudlims.com/integrate-ai-with-biospecimen-management-systems-to-transform-biobanking/ [Google Scholar] [Crossref]

22. Towards Healthcare. Biospecimen procurement market uptrends 16.04% CAGR by 2034. Market analysis report. Published April 2025. [Google Scholar] [Crossref]

23. Academic Clinical Trials Accelerating Clinical Trials in the EU (ACT EU). Revised ICH E6(R3) principles and Annex 1 published. Published January 14, 2025. [Google Scholar] [Crossref]

24. Association for the Accreditation of Human Research Protection Programs (ACRP). FDA publishes ICH E6(R3): What it means for U.S. clinical trials. Published September 2025. [Google Scholar] [Crossref]

25. Clinical Trials Toolkit. Summary of key changes in the ICH E6(R3) guidelines. Updated March 28, 2025. https://www.ct-toolkit.ac.uk/news/summary-key-changes-ich-e6-r3-guidelines [Google Scholar] [Crossref]

26. Peck KA, Disis ML, Peterson MC, et al. Domestic and international shipping of biospecimens. Methods Mol Biol. 2019;1897:27-38. doi:10.1007/978-1-4939-8935-5_4 [Google Scholar] [Crossref]

• Contributory Effect of Adenosine Triphosphate (ATP) To Male Infertility